These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38140003)

  • 1.
    Ferro-Flores G; Ocampo-García B; Cruz-Nova P; Luna-Gutiérrez M; Bravo-Villegas G; Azorín-Vega E; Jiménez-Mancilla N; Michel-Sánchez E; García-Pérez O; Lara-Almazán N; Santos-Cuevas C
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and Preclinical Assessment of
    Trujillo-Benítez D; Luna-Gutiérrez M; Ferro-Flores G; Ocampo-García B; Santos-Cuevas C; Bravo-Villegas G; Morales-Ávila E; Cruz-Nova P; Díaz-Nieto L; García-Quiroz J; Azorín-Vega E; Rosato A; Meléndez-Alafort L
    Molecules; 2022 Jan; 27(1):. PubMed ID: 35011496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel small
    Liang Z; Hu X; Hu H; Wang P; Cai J
    Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Imaging of Tumor PD-L1 Expression Using [
    Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
    Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
    Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
    Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of
    Fan M; Yao J; Zhao Z; Zhang X; Lu J
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a New
    Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
    Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of
    Luna-Gutiérrez M; Cruz-Nova P; Jiménez-Mancilla N; Oros-Pantoja R; Lara-Almazán N; Santos-Cuevas C; Azorín-Vega E; Ocampo-García B; Ferro-Flores G
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and preliminary biological evaluation of a novel
    Zhu D; Xu X; Zou P; Liu Y; Wang H; Han G; Lu C; Xie M
    Bioorg Med Chem Lett; 2023 Nov; 96():129496. PubMed ID: 37797805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter-rater and intra-rater agreement of [
    Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
    EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Kaihani S; Sadeghzadeh N; Abediankenari S; Abedi SM
    Ann Nucl Med; 2022 Nov; 36(11):976-985. PubMed ID: 36097232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical development and characterisation of
    Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
    Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
    Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
    Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Du Y; Chen Z; Duan X; Yan P; Zhang C; Kang L; Wang R
    Ann Nucl Med; 2022 Apr; 36(4):360-372. PubMed ID: 35032308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter- and intraobserver agreement of the quantitative assessment of [
    Hughes DJ; Chand G; Goh V; Cook GJR
    EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression.
    Morales-Avila E; Ferro-Flores G; Ocampo-García BE; De León-Rodríguez LM; Santos-Cuevas CL; García-Becerra R; Medina LA; Gómez-Oliván L
    Bioconjug Chem; 2011 May; 22(5):913-22. PubMed ID: 21513349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
    Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
    Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.